MedPath

CytoSorbents Seeks Approval for DrugSorb-ATR in Canada to Reduce Bleeding in Heart Surgery

• CytoSorbents has submitted a Medical Device License application to Health Canada for DrugSorb-ATR, targeting reduced bleeding during CABG surgery in patients on ticagrelor. • The application follows successful MDSAP certification, ensuring compliance with quality management system requirements in Canada and the U.S. • Regulatory decisions from Health Canada and the U.S. FDA are anticipated in 2025, potentially improving the standard of care for heart attack patients. • The STAR-T trial data supports the application, demonstrating DrugSorb-ATR's safety and efficacy in reducing perioperative bleeding complications.

CytoSorbents Corporation has announced the submission of its DrugSorb™-ATR Medical Device License (MDL) application to Health Canada on November 1, 2024, coinciding with the receipt of its Medical Device Single Audit Program (MDSAP) certification. DrugSorb-ATR, an investigational medical device, aims to facilitate safe and timely coronary artery bypass graft (CABG) surgery in patients with acute coronary syndromes (ACS) who are on the blood-thinning drug ticagrelor (Brilinta®, AstraZeneca). The Canadian MDL application follows the Company's DrugSorb-ATR U.S. Food and Drug Administration (FDA) De Novo filing, which is currently under substantive review.

Addressing a Critical Unmet Need

The use of ticagrelor, a blood-thinning agent, is common in heart attack patients. However, it poses a significant challenge when CABG surgery is required. Current guidelines recommend delaying surgery by three to five days to allow the drug to “washout” and reduce the risk of severe perioperative bleeding. DrugSorb-ATR is designed to mitigate this risk by removing ticagrelor from the patient's blood, potentially enabling earlier and safer surgery.

Regulatory Pathway and Expectations

“We are excited to have now submitted DrugSorb-ATR for marketing approval in both the U.S. and Canada,” stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. He added that the MDSAP certification is a key regulatory milestone, with the U.S. FDA accepting MDSAP certification and audit reports as a substitute for routine Agency inspections, if required. The company anticipates regulatory decisions in 2025, with Health Canada potentially preceding the FDA.

Clinical Evidence and Market Potential

The application is supported by data from the 140-patient North American pivotal STAR-T trial, a randomized, double-blind, sham-controlled study. This trial evaluated the safety and efficacy of DrugSorb-ATR in patients undergoing urgent cardiac surgery on ticagrelor, comparing perioperative bleeding complications in patients treated with the device versus those operated on without it. According to Dr. Chan, a future Health Canada approval of DrugSorb-ATR has the potential to improve the standard of care in heart attack patients requiring CABG surgery by enabling safe and timely surgery while eliminating treatment delays that expose patients to additional risk and consume valuable hospital resources.

About CytoSorbents Corporation

CytoSorbents Corporation (NASDAQ: CTSO) is focused on blood purification technologies for critical care. Their proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorb®, the company's lead product, is approved in the European Union and distributed in 76 countries worldwide, with over 250,000 devices used cumulatively to date. In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Capricor Therapeutics Completes FDA Submission for Deramiocel in DMD Cardiomyopathy

Capricor Therapeutics has completed its Biologics License Application (BLA) submission to the FDA for deramiocel to treat Duchenne muscular dystrophy (DMD) cardiomyopathy.
The BLA is supported by data from Phase 2 HOPE-2 and HOPE-2 Open Label Extension (OLE) trials, showing attenuation of cardiac implications of DMD.

CMS Proposes Medicare Coverage for Transcatheter Tricuspid Valve Replacement

CMS proposes Medicare coverage for transcatheter tricuspid valve replacement for severe, symptomatic tricuspid regurgitation, potentially benefiting Edwards Lifesciences' Evoque valve.
The decision utilizes Coverage with Evidence Development, requiring data collection through clinical trials or registries to assess the treatment's effectiveness.

Theralase Expands Bladder Cancer Clinical Trial with New Sites and Promising Phase II Data

Theralase has launched new clinical study sites in the U.S. and Canada for its Phase II trial of Ruvidar™ in BCG-unresponsive NMIBC.
Phase II data shows a 61.9% complete response rate among patients, with 43.6% maintaining this response for at least 12 months.

Zydus Healthcare to Conduct Phase III Trial for Glycopyrrolate/Indacaterol Inhaler

Zydus Healthcare will conduct a Phase III clinical trial for its fixed-dose combination of glycopyrrolate and indacaterol metered-dose inhalation, as recommended by the CDSCO panel.
The decision follows a review of Zydus Healthcare's bioequivalence study report and justification for a Phase III clinical trial waiver by the Subject Expert Committee (SEC).

CMS Grants Transitional Payment for Renal Denervation Devices from Medtronic and Recor

The Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment status to Medtronic and Recor for their renal denervation devices.
This decision aims to encourage the adoption of these FDA-approved therapies for hypertension by providing additional funding to hospitals.

Imricor Advances Towards Regulatory Approval in US and Europe for MRI-Guided Cardiac Ablation Technology

Imricor's FDA premarket approval review for its initial module was successfully completed ahead of schedule, marking a significant step toward US approval.
In Europe, the Vision-MR Ablation Catheter 2.0 is awaiting final certification after a positive audit, aligning with the stringent Medical Device Regulations (MDR).

CytoSorbents' DrugSorb-ATR Receives FDA Priority Review for Bleeding Reduction in Heart Surgery

CytoSorbents has submitted a De Novo marketing application to the FDA for DrugSorb™-ATR, aimed at reducing perioperative bleeding in CABG surgery patients.
The FDA has granted DrugSorb-ATR a Breakthrough Device Designation, making it eligible for priority review and potentially accelerating the approval process.

Capricor Therapeutics Advances Deramiocel for Duchenne Muscular Dystrophy Cardiomyopathy

Capricor Therapeutics plans to file a Biologics License Application (BLA) with the FDA for deramiocel to treat Duchenne muscular dystrophy (DMD) cardiomyopathy.
The BLA will be supported by cardiac data from Phase 2 HOPE-2 and HOPE-2 OLE trials, compared with natural history data.

Research Ethics Board Approves Amendment to Canadian COVID-19 Treatment Trial to Include LSALT Peptide

The Research Ethics Board at Sunnybrook Research Institute has approved an amendment to the CATCO trial protocol to include LSALT Peptide, a drug candidate by Arch Biopartners Inc., for treating organ damage caused by inflammation, in a new arm of the trial. The next step is seeking Health Canada's approval before dosing begins.

Izotropic Files Pre-Submission Application With U.S. FDA for Breast CT Imaging System

Izotropic Corporation has taken a significant step towards market approval for its Breast CT Imaging System by filing a Pre-Submission Application with the U.S. FDA. This move marks a pivotal moment in the company's journey to revolutionize breast cancer imaging, aiming to provide a less painful and more efficient diagnostic tool compared to traditional mammography.

Reference News

[1]
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb ...
morningstar.com · Nov 4, 2024

CytoSorbents submits DrugSorb-ATR MDL application to Health Canada, targeting CABG-related bleeding reduction with ticag...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy